3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Sarcoma
2
Mesothelioma, Malignant
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
MSI-H Colorectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
pembrolizumab
3
tislelizumab
2
spartalizumab
1
regorafenib
1
entinostat
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Interleukin-12 Subunit p35
1
Immunotherapy
1
Fentanyl
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
regorafenib
×
Other solid neoplasm
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn